| 2024-05-08 | -40.7% | legal | SEC EDGAR | NPCE 8-K: 2.02 and (SEC Filing) |
| 2023-01-09 | +39.2% | legal | SEC EDGAR | NPCE 8-K: 2.02, 5.02, 7.01 (SEC Filing) |
| 2025-11-04 | +38.9% | earnings | Seeking Alpha | NeuroPace GAAP EPS of -$0.11 beats by $0.09, revenue of $27.4M beats by $2.77M |
| 2025-11-04 | +38.9% | legal | SEC EDGAR | NPCE 8-K: 2.02 and (SEC Filing) |
| 2025-11-05 | +36.7% | earnings | Seeking Alpha | NeuroPace raises 2025 revenue and gross margin guidance amid record RNS growth and DIXI wind-down |
| 2025-11-05 | +36.7% | earnings | Seeking Alpha | NeuroPace, Inc. (NPCE) Q3 2025 Earnings Call Transcript |
| 2025-05-14 | +31.3% | earnings | Seeking Alpha | NeuroPace reports Q1 results; raises FY25 outlook |
| 2025-05-14 | +31.3% | news | Seeking Alpha | NeuroPace outlines 20%+ CAGR through 2027 as RNS business momentum accelerates |
| 2025-05-14 | +31.3% | earnings | Seeking Alpha | NeuroPace, Inc. (NPCE) Q1 2025 Earnings Call Transcript |
| 2025-05-14 | +31.3% | earnings | Seeking Alpha | NeuroPace, Inc. 2025 Q1 - Results - Earnings Call Presentation |
| 2025-05-27 | -31.0% | news | Seeking Alpha | NeuroPace falls after setback in trial for neuromodulation system |
| 2025-05-27 | -31.0% | legal | SEC EDGAR | NPCE 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-05-27 | -31.0% | earnings | Yahoo Finance | Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data? - Yahoo Finance |
| 2024-11-12 | +25.9% | legal | SEC EDGAR | NPCE 8-K: 2.02 and (SEC Filing) |
| 2024-01-08 | +19.1% | legal | SEC EDGAR | NPCE 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-11-05 | +18.7% | news | GuruFocus | Revelation Capital Management, LLC's NeuroPace Inc(NPCE) Holding History - GuruFocus |
| 2024-04-04 | +17.2% | analyst | TradingView | NPCE Forecast — Price Target — Prediction for 2027 - TradingView |
| 2025-05-13 | +15.9% | legal | SEC EDGAR | NPCE 8-K: 2.02 and (SEC Filing) |
| 2023-03-02 | -15.7% | legal | SEC EDGAR | NPCE 8-K: 2.02 and (SEC Filing) |
| 2021-11-10 | -14.4% | legal | SEC EDGAR | NPCE 8-K: 2.02 and (SEC Filing) |
| 2025-11-24 | +14.0% | news | Stock Titan | NeuroPace (Nasdaq: NPCE) gets 47% Medicare boost for RNS System replacements - Stock Titan |
| 2022-01-11 | +13.2% | legal | SEC EDGAR | NPCE 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-02-14 | +10.9% | news | Seeking Alpha | NeuroPace stock dips after pricing $65M share offering |
| 2025-02-14 | +10.9% | legal | SEC EDGAR | NPCE 8-K: 1.01 (SEC Filing) |
| 2023-08-08 | +10.9% | legal | SEC EDGAR | NPCE 8-K: 2.02 and (SEC Filing) |
| 2026-04-01 | +10.6% | news | Simply Wall St. | How Shifting Margin Assumptions Are Rewriting The NeuroPace (NPCE) Investment Narrative |
| 2026-04-01 | +10.6% | news | Cổng thông tin điện tử Tỉnh Sơn La | NPCE Stock Analysis: Neuropace Inc. 7 percent daily gain medtech investor outlook - Cổng thông tin điện tử Tỉnh Sơn La |
| 2025-02-18 | +8.7% | legal | SEC EDGAR | NPCE 8-K: 8.01 and (SEC Filing) |
| 2022-11-08 | -8.3% | legal | SEC EDGAR | NPCE 8-K: 2.02 and (SEC Filing) |
| 2021-08-12 | -8.0% | legal | SEC EDGAR | NPCE 8-K: 2.02 and (SEC Filing) |
| 2024-02-07 | +6.8% | legal | SEC EDGAR | NPCE 8-K: 5.02 (SEC Filing) |
| 2026-02-13 | +6.5% | news | DirectorsTalk Interviews | Neuropace, Inc. (NPCE) Stock Analysis: A 34% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews |
| 2023-12-04 | -6.1% | legal | SEC EDGAR | NPCE 8-K: 1.01 (SEC Filing) |
| 2026-04-17 | +5.8% | news | DirectorsTalk Interviews | Neuropace, Inc. (NPCE) Stock Analysis: A Healthcare Innovator with a Promising 28% Potential Upside - DirectorsTalk Interviews |
| 2021-04-29 | -5.7% | news | StockInvest.us | Neuropace Stock Price Forecast. Should You Buy NPCE? - StockInvest.us |
| 2025-06-12 | -5.7% | news | PR Newswire | INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE - PR Newswire |
| 2025-05-06 | +5.5% | news | Intellectia AI | NPCE Forecast — Price Prediction for 2026. Should I Buy NPCE? - Intellectia AI |
| 2025-03-05 | -5.5% | earnings | Seeking Alpha | NeuroPace, Inc. (NPCE) Q4 2024 Earnings Call Transcript |
| 2026-01-23 | -5.3% | analyst | DirectorsTalk Interviews | Neuropace, Inc. (NPCE) Stock Analysis: A 12.97% Potential Upside With Strong Buy Ratings - DirectorsTalk Interviews |
| 2022-08-11 | -5.2% | legal | SEC EDGAR | NPCE 8-K: 1.01, 2.02 (SEC Filing) |
| 2025-02-20 | +4.5% | legal | SEC EDGAR | NPCE 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-11-03 | -4.4% | earnings | Yahoo Finance | NeuroPace Inc (NPCE) Q3 2025 Earnings Report Preview: What to Look For - Yahoo Finance |
| 2026-03-02 | -4.3% | news | Stock Titan | NeuroPace (NPCE) CMO has 358 shares withheld for RSU tax - Stock Titan |
| 2026-03-10 | +4.3% | news | Zacks | Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026 |
| 2026-03-10 | +4.3% | news | Zacks | NPCE RNS System Explained: Growth Drivers and Setup for 2026 |
| 2026-03-10 | +4.3% | news | Zacks | NeuroPace's Seizure ID and New Indication Could Expand RNS Demand |
| 2026-03-10 | +4.3% | news | TradingView | Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026 - TradingView |
| 2026-03-10 | +4.3% | news | TradingView | NPCE RNS System Explained: Growth Drivers and Setup for 2026 - TradingView |
| 2026-03-25 | +4.2% | news | Stock Titan | NeuroPace (NPCE) CMO has 1,341 shares withheld for RSU tax - Stock Titan |
| 2024-08-13 | -3.8% | legal | SEC EDGAR | NPCE 8-K: 2.02 and (SEC Filing) |
| 2025-05-28 | +3.7% | news | Yahoo Finance | NPCE Stock Tumbles Despite Positive One-Year Data From NAUTILUS Trial - Yahoo Finance |
| 2025-04-02 | +3.6% | earnings | Seeking Alpha | NeuroPace refocuses product portfolio; reaffirms 2025 revenue guidance |
| 2025-04-02 | +3.6% | legal | SEC EDGAR | NPCE 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-06-29 | +3.5% | news | Seeking Alpha | NeuroPace: Volatile, Uncertain, But Promising |
| 2025-08-12 | +3.4% | earnings | Seeking Alpha | NeuroPace GAAP EPS of -$0.26 misses by $0.04, revenue of $23.5M beats by $0.42M |
| 2025-08-12 | +3.4% | legal | SEC EDGAR | NPCE 8-K: 2.02 and (SEC Filing) |
| 2026-03-18 | -3.4% | analyst | Simply Wall St. | How The NeuroPace (NPCE) Story Is Shifting As Analysts Refresh Valuation Assumptions |
| 2023-04-13 | +3.3% | legal | SEC EDGAR | NPCE 8-K: 5.02 (SEC Filing) |
| 2026-04-02 | +3.2% | earnings | Zacks | NeuroPace (NPCE) Up 0.9% Since Last Earnings Report: Can It Continue? |
| 2026-04-02 | +3.2% | news | Zacks | Here's Why You Should Add NeuroPace Stock to Your Portfolio Now |
| 2026-04-02 | +3.2% | analyst | Zacks | Wall Street Analysts See a 41.29% Upside in NeuroPace (NPCE): Can the Stock Really Move This High? |
| 2026-04-02 | +3.2% | news | TradingView | Here's Why You Should Add NeuroPace Stock to Your Portfolio Now - TradingView |
| 2026-04-02 | +3.2% | earnings | Yahoo Finance | NeuroPace (NPCE) Up 0.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance |
| 2023-08-17 | +2.8% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2025-01-28 | +2.8% | legal | SEC EDGAR | NPCE 8-K: 2.02, 7.01, 8.01 (SEC Filing) |
| 2025-01-08 | -2.5% | earnings | Seeking Alpha | NeuroPace reports preliminary Q4 revenue |
| 2025-01-08 | -2.5% | legal | SEC EDGAR | NPCE 8-K: 2.02, 5.02, 8.01 (SEC Filing) |
| 2026-03-05 | +2.4% | news | Business Wire | NeuroPace to Present at the Leerink Global Healthcare Conference |
| 2026-03-05 | +2.4% | executive | Investing.com | Neuropace (NPCE) chief medical officer sells $399k in stock - Investing.com |
| 2026-03-05 | +2.4% | earnings | Stock Titan | Epilepsy device maker NeuroPace joins Leerink 2026 healthcare lineup - Stock Titan |
| 2026-04-21 | +2.4% | news | Stock Titan | NeuroPace (NASDAQ: NPCE) plans 2026 virtual vote on board and auditor - Stock Titan |
| 2023-11-06 | -1.9% | legal | SEC EDGAR | NPCE 8-K: 2.02 and (SEC Filing) |
| 2021-10-19 | -1.9% | legal | SEC EDGAR | NPCE 8-K: 5.02 (SEC Filing) |
| 2026-03-04 | -1.8% | earnings | Seeking Alpha | NeuroPace reiterates $98M–$100M 2026 revenue target while advancing AI and IGE pipeline |
| 2026-03-04 | -1.8% | earnings | Seeking Alpha | NeuroPace, Inc. (NPCE) Q4 2025 Earnings Call Transcript |
| 2026-03-04 | -1.8% | news | The Motley Fool | Why NeuroPace Stock Was Inching Higher on Wednesday - The Motley Fool |
| 2022-03-19 | +1.7% | news | StockInvest.us | NPCE Insider Trading (NeuroPace, Inc. stock) - StockInvest.us |
| 2023-07-19 | -1.6% | legal | SEC EDGAR | NPCE 8-K: 5.02 and (SEC Filing) |
| 2025-04-14 | -1.5% | news | Seeking Alpha | NeuroPace expects minimal impact of tariffs on its operations and financial results |
| 2025-08-13 | -1.4% | earnings | Seeking Alpha | NeuroPace raises 2025 revenue guidance to $94M-$98M as RNS System drives record growth |
| 2025-08-13 | -1.4% | earnings | Seeking Alpha | NeuroPace, Inc. 2025 Q2 - Results - Earnings Call Presentation |
| 2025-08-13 | -1.4% | earnings | Seeking Alpha | NeuroPace, Inc. (NPCE) Q2 2025 Earnings Call Transcript |
| 2025-06-04 | -1.4% | legal | Seeking Alpha | NeuroPace secures $75M credit facility with MidCap Financial |
| 2025-06-04 | -1.4% | legal | SEC EDGAR | NPCE 8-K: 1.01, 1.02, 2.03, 7.01 (SEC Filing) |
| 2025-03-04 | -1.4% | earnings | Seeking Alpha | NeuroPace, Inc. 2024 Q4 - Results - Earnings Call Presentation |
| 2025-03-04 | -1.4% | earnings | Seeking Alpha | NeuroPace GAAP EPS of -$0.18 beats by $0.04, revenue of $21.47M beats by $0.33M |
| 2025-03-04 | -1.4% | legal | SEC EDGAR | NPCE 8-K: 2.02 and (SEC Filing) |
| 2025-03-04 | -1.4% | earnings | Stock Titan | How NeuroPace's Record Revenue Growth Is Reshaping Its Financial Future - Stock Titan |
| 2026-03-23 | +1.4% | news | Stock Titan | NeuroPace (NPCE) director receives 1,826-share equity grant in lieu of cash fees - Stock Titan |
| 2026-03-23 | +1.4% | news | Stock Titan | NeuroPace (NPCE) director gets 1,153-share stock grant as board fees - Stock Titan |
| 2024-03-05 | +1.3% | legal | SEC EDGAR | NPCE 8-K: 2.02 and (SEC Filing) |
| 2026-03-03 | -1.2% | earnings | Seeking Alpha | NeuroPace GAAP EPS of -$0.08 beats by $0.08, revenue of $26.6M beats by $1.81M |
| 2026-03-03 | -1.2% | legal | SEC EDGAR | NPCE 8-K: 2.02 and (SEC Filing) |
| 2026-03-03 | -1.2% | earnings | Quiver Quantitative | Neuropace Inc. (NPCE) Stock Rises on Q4 2025 Earnings - Quiver Quantitative |
| 2026-03-03 | -1.2% | earnings | Yahoo Finance | NeuroPace, Inc. (NPCE) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance |
| 2026-03-03 | -1.2% | news | Stock Titan | NeuroPace brain implant cuts seizures 77% amid 40%+ Medicare pay hikes - Stock Titan |
| 2025-06-24 | -1.2% | executive | Seeking Alpha | NeuroPace appoints Patrick Williams as CFO |
| 2025-06-24 | -1.2% | legal | SEC EDGAR | NPCE 8-K: 5.02, 7.01 (SEC Filing) |
| 2022-05-12 | -1.1% | legal | SEC EDGAR | NPCE 8-K: 2.02 and (SEC Filing) |
| 2026-01-09 | -1.1% | earnings | simplywall.st | NeuroPace (NASDAQ:NPCE) Has Debt But No Earnings; Should You Worry? - simplywall.st |
| 2026-01-15 | +0.9% | news | Seeking Alpha | NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript |
| 2026-01-15 | +0.9% | news | Seeking Alpha | NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow |
| 2026-03-24 | +0.9% | news | Stock Titan | Director at NeuroPace (NPCE) receives 913-share stock grant and controls large fund stake - Stock Titan |
| 2026-03-24 | +0.9% | news | Stock Titan | NeuroPace director granted 865 shares at $13 | NPCE Insider Trading - Stock Titan |
| 2022-03-10 | +0.9% | legal | SEC EDGAR | NPCE 8-K: 2.02 and (SEC Filing) |
| 2025-04-03 | +0.8% | news | Seeking Alpha | Stryker, Boston Scientific down as new tariffs impact medtech industry |
| 2025-02-13 | +0.8% | news | Seeking Alpha | NeuroPace announces proposed public offering of $65M of common stock |
| 2023-05-04 | +0.7% | legal | SEC EDGAR | NPCE 8-K: 2.02 and (SEC Filing) |
| 2026-04-10 | +0.7% | news | Business Wire | NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference |
| 2026-04-10 | +0.7% | earnings | Stock Titan | Epilepsy device maker NeuroPace streams Needham talk on April 14 - Stock Titan |
| 2026-02-24 | -0.5% | earnings | Yahoo Finance | NeuroPace, Inc. (NPCE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance |
| 2023-06-28 | -0.4% | legal | SEC EDGAR | NPCE 8-K: 5.02 and (SEC Filing) |
| 2026-01-13 | -0.3% | earnings | Seeking Alpha | NeuroPace sees Q4 revenue of about $26.6M |
| 2026-01-13 | -0.3% | earnings | Stock Titan | Epilepsy device maker NeuroPace posts 25% growth, outlines 2026 plan - Stock Titan |
| 2024-05-11 | +0.2% | earnings | MarketBeat | NeuroPace (NPCE) Stock Forecast and Price Target 2026 - MarketBeat |
| 2021-06-03 | +0.2% | legal | SEC EDGAR | NPCE 8-K: 2.02 and (SEC Filing) |
| 2022-10-07 | -0.2% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for NeuroPace (NPCE) - Zacks Investment Research |
| 2026-04-26 | — | earnings | MarketBeat | NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat |
| 2026-04-26 | — | analyst | MSN | Wall Street analysts see a 41.29% upside in NeuroPace (NPCE): Can the stock really move this high? - MSN |
| 2021-04-26 | — | legal | SEC EDGAR | NPCE 8-K: 5.03, 8.01 (SEC Filing) |